NCT07657468 Docosahexaenoic acid Analgesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07657468—Phase II, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids as an Adjunct to Morphine in Acute Postoperative Pain (O3MORPH)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07657468 is a hot trial to watch

Analgesia is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07657468 is notable because it evaluates Docosahexaenoic acid in a Phase 2 design while Total morphine requirement in the 24 hours post-surgery. serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of 40 participants across Argentina shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: Total morphine requirement in the 24 hours post-surgery. (24hs)
• Secondary: Average Pain Score (24 hs)
• Secondary: Average Nausea Score (24 hs)
• Secondary: Average Pruritus Score (24 hs)
• Secondary: Average Vomiting Score (24 hs)

Benchmark readouts in the surrounding field

• Comparative Efficacy of Two Different Oral Dosage Forms of Acetaminophen for Post-operative Analgesia in Bariatric Surgery Patients (Phase 2): Pain Control(Mean) = 3.8 Units on a scale (0 to 10) (Standard Deviation, 1.5); Pain Control(Mean) = 3.6 Units on a scale (0 to 10) (Standard Deviation, 1.3)
• The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery (Phase 2): Overall Benefit of Analgesia Score (OBAS)(Mean) = 4.0 OBAS Score (Inter-Quartile Range, 2 - 6); Overall Benefit of Analgesia Score (OBAS)(Mean) = 4.0 OBAS Score (Inter-Quartile Range, 2 - 6)
• A Phase 3b, Randomized, Open-Label Study of HTX-011 as the Foundation of a Non-opioid, Multimodal Analgesic Regimen to Decrease Opioid Use Following Unilateral Open Inguinal Herniorrhaphy (Phase 3): Proportion of Subjects Who do Not Receive an Opioid Prescription Through the Day 15 Visit = 97 Participants ; Proportion of Subjects Who do Not Receive an Opioid Prescription Through the Day 15 Visit = 95 Participants

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Docosahexaenoic acid (Preclinical; AHSG x TRPC3 x TRPC6); Morphine Sulfate (Approved; Opioid receptors)

Company & Deal Intelligence context: Not reported

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

NCT07657468 is a focused lens on Analgesia development. Its value will be determined by whether Docosahexaenoic acid can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.